Institutional Review Board, Hospital for Special Surgery
August 16, 2010
The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.
For further information, see Understanding Clinical Trials.
Keith R. Reinhardt, MD
Sommer Hammoud, MD
Andrea Bowers, MD
David W. Altchek, MD
Answorth A. Allen, MD
Robert G. Marx, MD
Andrew D. Pearle, MD
Anil S. Ranawat, MD
Anne M. Kelly, MD
Beth E. Shubin Stein, MD
Bryan T. Kelly, MD
David M. Dines, MD
Joshua S. Dines, MD
Edward V. Craig, MD. MPH
Howard Anthony Rose, MD
Jo A. Hannafin, MD, PhD
John D. MacGillivray, MD
Michael J. Maynard, MD
Riley J. Williams III, MD
Russell F. Warren, MD
Sabrina M. Strickland, MD
Scott A. Rodeo, MD
Stephen Fealy, MD
Steve J. O’Brien, MD, MBA
Struan H. Coleman, MD, MPH
Thomas L. Wickiewicz, MD
Review of outcomes of revision ACL reconstruction in adolescent patients ages 12-18.
Review of outcomes of revision ACL reconstruction in adolescent patients ages 12-18.
Keith Reinhardt, MD
krr9009@gmail.com
646-678-4402